UK sovereign AI fund backs Potential Sciences in chemistry AI funding round

Traders Union
All News
Geopolitics & Trade
UK backs Potential Sciences AI

Highlights

Potential Sciences secured eight-figure funding from the UK Sovereign AI fund and access to national AI supercomputers including Isambard-AI on 5 November.
The company claims its physics-based AI models can cut chemical design costs by 100 times, attracting investors like Twin Path Ventures and Stripe co-founder Patrick Collison.
The government extended Sovereign AI with an additional £140 million post-Budget, expanding support to Physical and Industrial AI and targeting domestic innovation and jobs.

Funding round and compute support

As reported by GOV.UK, Potential Sciences has secured backing from the UK Government’s Sovereign AI venture fund as part of an eight-figure fundraise announced on Thursday 5 November. The support also includes access to compute through the AI Research Resource, the UK’s national suite of advanced supercomputers, including the Isambard-AI system in Bristol.

The startup is developing AI tools for chemistry and medicine design using models based on the laws of physics rather than relying mainly on historical experimental data. Potential Sciences says that approach could make the calculations needed to design chemicals 100 times cheaper, which would help open up research areas that are currently uneconomic.

Founder and chief executive Hatem Helal said the company has rebuilt quantum chemistry for GPUs so that high-accuracy calculations are affordable at the scale AI systems need. Other investors in the round include Twin Path Ventures, Odyssey, Portfolio Ventures, Blue Wire Capital, rule30, Nauta Capital and Lightfield Equity, alongside angel investors including Stripe co-founder Patrick Collison and Recursion co-founder and former chief executive Chris Gibson.

UK industrial strategy and life sciences impact

The investment reflects the UK government’s wider effort to keep high-potential AI companies anchored in Britain and to link AI development with scientific research, advanced manufacturing and life sciences. Ministers say the technology could help address bottlenecks in chemical and drug discovery, with possible applications in areas such as cancer and Parkinson’s research.

AI Minister Kanishka Narayan said solving chemistry’s data bottleneck could allow researchers to explore treatments for diseases that are currently overlooked because of cost or limited commercial focus. Science Minister Chris McDonald said the investment shows how combining British scientific research with AI could support medical breakthroughs and broader innovation.

The announcement comes a week after the Budget, when the Chancellor confirmed a further £140 million for Sovereign AI, including £60 million for fund investments and £80 million for its R&D Procurement Scheme. The government also said Sovereign AI is expanding into Physical and Industrial AI, adding to existing support for startups with a meaningful UK presence and domestic job creation.

Our earlier coverage of AstraZeneca’s AI-driven drug discovery partnership with insitro detailed a multi-year collaboration targeting MASH and cardiomyopathies, including a $40 million upfront payment and potential milestone payouts approaching $1.5 billion. We noted how insitro’s “Virtual Human” platform aims to help identify disease biology and advance targets to development-candidate stage, while AstraZeneca would take over and fund later clinical trials—highlighting the broader push to use AI to speed early drug discovery and improve target selection.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.